The demise of calcium-based phosphate binders

The Lancet

Volumn 382, Issue 9900, 2013, Pages 1232-1234

  Ortiz, Alberto ^a   Sanchez Niño, Maria Dolores ^b  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; CALCIUM; CALCIUM CARBONATE; PHOSPHATE BINDING AGENT; VITAMIN D; CALCIUM DERIVATIVE; CHELATING AGENT; PHOSPHATE;

ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; CALCIUM EXCRETION; CALCIUM INTAKE; CALCIUM URINE LEVEL; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; CORONARY ARTERY CALCIFICATION; DIALYSIS ENCEPHALOPATHY; DISEASE ASSOCIATION; FOLLOW UP; HOSPITAL PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; META ANALYSIS (TOPIC); MILK ALKALI SYNDROME; NOTE; POPULATION; PRACTICE GUIDELINE; PREMATURE MORTALITY; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SOFT TISSUE CALCIFICATION; SYSTEMATIC REVIEW (TOPIC); FEMALE; MALE; MORTALITY;

CALCIUM COMPOUNDS; CHELATING AGENTS; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MALE; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84887375430     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61165-4     Document Type: Note

References (14)

1. Jamal, SA, Vandermeer, B, Raggi, P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet, 2013 published online July 19. http://dx.doi.org/10.1016/S0140-6736(13)60897-1.
2. Gonzalez-Parra, E, Tuñón, J, Egido, J, Ortiz, A, Phosphate: a stealthier killer than previously thought?. Cardiovasc Pathol 21 (2012), 372–381.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113 (2009), S1–13.
4. Alfrey, AC, LeGendre, GR, Kaehny, WD, The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294 (1976), 184–188.
5. Slatopolsky, E, Weerts, C, Lopez-Hilker, S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315 (1986), 157–161.
6. Bolland, MJ, Grey, A, Avenell, A, Gamble, GD, Reid, IR, Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ, 342, 2011, d2040.
7. Block, GA, Wheeler, DC, Persky, MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23 (2012), 1407–1415.
8. Chertow, GM, Burke, SK, Lazarus, JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29 (1997), 66–71.
9. Tonelli, M, Pannu, N, Manns, B, Oral phosphate binders in patients with kidney failure. N Engl J Med 362 (2010), 1312–1324.
10. Baigent, C, Landray, MJ, Reith, C, et al., for the SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
11. Wüthrich, RP, Chonchol, M, Covic, A, Gaillard, S, Chong, E, Tumlin, JA, Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 8 (2013), 280–289.
12. Ohnishi, M, Razzaque, MS, Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 24 (2010), 3562–3571.
13. Hu, MC, Shi, M, Zhang, J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22 (2011), 124–136.
14. Moreno, JA, Izquierdo, MC, Sanchez-Niño, MD, et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol 22 (2011), 1315–1325.